Vendor Intelligence Report: Risynth Bio

Executive summary

Across 8 Finnrick lab tests, Risynth Bio has 7 pass / 1 fail for an overall pass rate of 88%. The record is small and concentrated, but not weak: tirzepatide is the cleaner read, while retatrutide carries the only Finnrick failure. Under stricter grading, the rating picture narrows, so the buyer signal is product-specific rather than catalog-wide.

The counterparty record is the tension. Formation records and WHOIS line up on a same-day 2025 launch signal, tied to a Delaware corporation with a good-standing problem in the field record and no named officers, founders, or scientific staff in the public trail. The listed Houston address resolves to a post office, while Texas records and the Risynth Lab migration trail complicate the operating-footprint picture.

Risynth's COA posture is better than a pure self-attested storefront: its certificates page includes Kovera Labs materials alongside Finnrick and Chromate reports, and the dossier tests the captive-lab hypothesis against a multi-client Kovera corpus. But buyer recourse is thin: Cash App, Venmo, and ACH are the documented rails, with instructions to omit product names from payment memos.

The result is a mixed, directional read: Risynth Bio is a plausible short-list vendor for tirzepatide buyers who can tolerate opacity, a more cautious choice for retatrutide, and largely unproven by Finnrick outside those two tested products.

Inside the full report:

• Appendix A — Finnrick Laboratory Data with per-product pass/fail rates, rating trajectories, and methodology-divergence charts for both tested products
• Delaware and Texas corporate-record exhibits for RISYNTH CORP., including standing, taxpayer, registered-agent, and SOS-status findings
• WHOIS, Wayback, certificate-transparency, privacy-policy, and migration-banner analysis for risynthbio.com and risynthlab.com
• COA provenance review covering Kovera Labs, Finnrick Analytics, Chromate, and the captive-lab hypothesis
• Payment-method exhibit and buyer-recourse analysis for Cash App, Venmo, ACH, and memo restrictions
• Promotion, reputation, enforcement, import-record, and open-lead/dead-end findings

Risk assessment

• Corporate accountability and legal-standing risk — high: No public officers, directors, or beneficial owner were identified, and field-captured Delaware records report RISYNTH CORP. is not in good standing.
• Buyer-recourse/payment risk — high: Cash App, Venmo, and ACH are the only documented rails; no credit-card chargeback path, and the payment page instructs buyers not to include product names.
• Operational-location and Texas-registration risk — medium: The listed Houston address is a USPS post office, while Texas records show SOS status Not Registered and no Texas registered agent identified.
• Undisclosed reseller supply-chain risk — medium: Shipping language indicates Risynth receives inventory before fulfillment, but no manufacturer, supplier, origin, or import record was disclosed or identified.
• Limited independent testing coverage beyond GLP-1s — medium: Finnrick testing covers only tirzepatide and retatrutide across 8 tests; the rest of the 49-product catalog lacks product-specific Finnrick coverage.
• Retatrutide consistency risk — medium: Retatrutide has 4 Finnrick tests with 3 pass / 1 fail and a current 78.57% rating; tirzepatide is stronger at 4/4 pass and 82.05%.
• Commercial/product-identity transparency risk — medium: Prices require account registration, and GLP-1 compounds are marketed under internal codes including RB-S1, RB-T2, RB-R3, CAGR, and Tesa.
• Brand-migration and channel-verification risk — medium: Risynthlab.com, a privacy-policy domain slip, and a Trustpilot profile under the old domain create channel ambiguity; no authorized-reseller or anti-counterfeit list was identified.